

## Abstract

# Box–Behnken Assisted HPLC Development of Simultaneous Determination of Doxorubicin and Vorinostat Encapsulated into Polymeric Nanoparticles <sup>†</sup>

Maria Sokol <sup>1,\*</sup>, Ivan Gulyaev <sup>1,2</sup>, Mariia Mollaeva <sup>1</sup> , Sergey Kuznetsov <sup>3</sup>, Vladimir Zenin <sup>4</sup>, Maksim Klimenko <sup>1,2</sup>, Nikita Yabbarov <sup>1</sup> , Margarita Chirkina <sup>1</sup> and Elena Nikolskaya <sup>1,\*</sup> 

<sup>1</sup> N.M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, 4, Kosygina Str., 119334 Moscow, Russia

<sup>2</sup> Faculty of Pharmaceutical Technologies and Biomedical Products, Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russia

<sup>3</sup> National Research Center “Kurchatov Institute”, 123098 Moscow, Russia

<sup>4</sup> Federal State Institution, Federal Research Centre, Fundamentals of Biotechnology, Russian Academy of Sciences, 119071 Moscow, Russia

\* Correspondence: mariyabsokol@gmail.com (M.S.); elenanikolskaja@gmail.com (E.N.)

<sup>†</sup> Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: <https://ecmc2022.sciforum.net/>.

**Keywords:** Box–Behnken design; doxorubicin; nanoparticles; PLGA; validation; vorinostat



**Citation:** Sokol, M.; Gulyaev, I.; Mollaeva, M.; Kuznetsov, S.; Zenin, V.; Klimenko, M.; Yabbarov, N.; Chirkina, M.; Nikolskaya, E. Box–Behnken Assisted HPLC Development of Simultaneous Determination of Doxorubicin and Vorinostat Encapsulated into Polymeric Nanoparticles. *Med. Sci. Forum* **2022**, *14*, 136. <https://doi.org/10.3390/ECMC2022-13493>

Academic Editor: Amélia Pilar Rauter

Published: 7 November 2022

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

The objects of the present study are nanoparticles (NPs) based on a copolymer of lactic and glycolic acids (PLGA), loaded with the anticancer drug doxorubicin (DOX-NP) and histone deacetylase inhibitor vorinostat (SAHA-NP) and developed for breast cancer treatment. Drug encapsulation into the PLGA matrix improves drug safety profiles and allows us to overcome multidrug resistance. In the current study, we developed a high-performance liquid chromatography method for the simultaneous determination of DOX-NP and SAHA-NP using a Box–Behnken design, followed by validation and NPs stability determination after sterilization treatment with  $\gamma$ -irradiation.

The separation was performed using a Nucleodur C-18 Gravity column (250 mm  $\times$  4.6 mm  $\times$  5  $\mu$ m). Samples were prepared by precipitating PLGA with dimethyl sulfoxide. Three independent variables were analyzed to determine the most optimal conditions: methanol concentration (0–20%), pH (2.5–4.5) and flow rate (0.8–1.2 mL/min). We evaluated the contributions of these variables to the peak resolution and retention time of the last peak of the analyte using a Box–Behnken design. Next, we simultaneously optimized all dependent variables and established their most optimal values using the desirability function.

The optimized method was accurate, precise and linear, in the range of 4.2–52.0  $\mu$ g/mL for both drugs ( $R^2 = 0.9999$  for vorinostat and  $R^2 = 0.9988$  for doxorubicin).  $\gamma$ -irradiation at a dose of 25 kGy resulted in a degradation of DOX-NP of less than 95%, while the amount of SAHA-NP impurities was 88%.

Thus, the developed method is suitable for simultaneous analysis of DOX-NP and SAHA-NP, including the analysis of impurities.

**Supplementary Materials:** The presentation material of this work is available online at <https://www.mdpi.com/article/10.3390/ECMC2022-13493/s1>.

**Author Contributions:** Conceptualization, M.S. and E.N.; validation, M.S., I.G. and V.Z.; formal analysis, M.M.; investigation, S.K.; resources, M.C.; writing—original draft preparation, M.S.; writing—review and editing, N.Y. and E.N.; visualization, M.K.; funding acquisition, E.N. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by the Russian Science Foundation research grant No. 22-25-00293, <https://rscf.ru/project/22-25-00293/>.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available at <https://doi.org/10.1002/jssc.202200731>.

**Conflicts of Interest:** The authors declare no conflict of interest.